High mortality among patients with cancer and COVID-19 infection: the experience of a Brazilian cancer center

• Autor(a) principal: Barros,Lilian Arruda do Rêgo
• Data de Publicação: 2021
• Outros Autores: Magalhães Filho,Marcos Aurélio Fonseca, Alves,Rafaela de Brito, Rebouças,Camilla Vieira de, Rodrigues,Cicilia Marques, Viu,Micaela Mazutti, Benedito,Vinicius de Lima, Yamada,Alayne Magalhães Trindade Domingues, del Giglio,Auro, Cruz,Felipe José Silva Melo
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Einstein (São Paulo)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082021000100244
• topic: Neoplasms; COVID-19; SARS-CoV-2; Coronavirus infections; Mortality; Pandemics; Fatal outcome

ABSTRACT Objective To evaluate the severity of COVID-19 in cancer patients to describe clinical and epidemiological factors associated with poor outcomes (mortality and need of intensive care unit admission or mechanical ventilation). Methods Retrospective data from patients with cancer and laboratory diagnosis of COVID-19, obtained between March 16 and May 29, 2020, were retrieved out of a cancer center database. Data analyzed included patient history, age, sex, comorbidities, types of cancer and anticancer therapy. Results This sample comprised 105 patients aged 18-92 years, 80.9% of whom were females. Dyspnea was the most prevalent initial symptom (30.4%) among patients who died (p<0.0001). Overall, 57.1% of patients had metastatic disease and 60% had poor performance status (Eastern Cooperative Oncologic Group ≥2) at the time of COVID-19 diagnosis. The overall mortality rate was 40.95%. Mortality rates were higher in male patients and those with poor performance status (p<0.0001). Conclusion This cohort is one of the largest Brazilian studies describing clinical and epidemiological features of patients with cancer and concurrent COVID-19. Findings of this study emphasize the vulnerability of cancer patients in the current pandemic, and indicate high mortality from COVID-19 among male cancer patients and cancer patients with poor performance status. This analysis may assist the selection of patients who may benefit from strict isolation and eventual discontinuation of anticancer therapy to reduce exposure to infection.